menu
    • menu
    [{"orgOrder":0,"company":"Levolta Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Zoledronic Acid Derivative","moa":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Levolta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Levolta Pharmaceuticals \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Levolta Pharmaceuticals \/ Tabuk Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Levolta Pharmaceuticals

    Menu

    Levolta Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Levolta Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Levolta Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zoledronic Acid Derivative

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II/ Phase III

                            Sponsor : Tabuk Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Levolta Pharmaceuticals Partners with Tabuk Pharmaceuticals for Commercialization of Investigational Osteoarth...

                            Details : The agreement aims for the commercialization of an investigational osteoarthritis (OA) therapy, VOLT01 (zoledronic acid), a patented novel combination drug, in the Middle East and Africa (MEA) region, excluding South Africa.

                            Brand Name : VOLT01

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 01, 2023

                            Lead Product(s) : Zoledronic Acid Derivative

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Tabuk Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth